In 2025, the MedTech industry moved from post-pandemic stabilization into a phase of strategic consolidation. While overall transaction volumes remained selective, total deal value surged to its highest level in more than a decade, underscoring a clear shift toward fewer, larger, and more strategic acquisitions. This trend was most visible in the rise of mega-deals centered on commercial-ready, revenue-generating platforms. A handful of blockbuster deals, including Abbott’s $23 billion acquisition of diagnostics firm Exact Sciences1Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision. (n.d.). Exact Sciences. https://www.exactsciences.com/news-events/press-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision and the $18.3 billion take-private of Hologic by Blackstone and TPG2Hologic to be Acquired by Blackstone and TPG for up to $79 per Share. (2025, October 21). Hologic. https://investors.hologic.com/press-releases/press-release-details/2025/Hologic-to-be-Acquired-by-Blackstone-and-TPG-for-up-to-79-per-Share/default.aspx announced late in the year, illustrated acquirers’ renewed appetite for scaled assets with established market traction.
Deal activity concentrated around high-growth therapeutic hotspots, like cardiovascular care, surgical robotics, and AI-enabled diagnostics. Acquirers increasingly pursued high-margin “adjacency stacking” strategies to strengthen their competitive positioning and build more integrated patient-care ecosystems. A notable example is Stryker’s acquisition of Inari Medical, adding a high-growth, procedure-driven venous intervention platform adjacent to its existing interventional and hospital-based businesses.
Finally, 2025 was marked by a pronounced focus on portfolio discipline. Leading players prioritized focus over diversification, divesting or spinning-off non-core or slower-growth assets to unlock value and redeploy capital toward innovation. Baxter’s separation of its renal care business into Vantive3Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company. (2025, February 3). Vantive Corporate. https://www.vantive.com/news/press-releases/baxter-kidney-care-now-vantive-new-standalone-vital-organ-therapy-company, finalized early 2025, set the tone at the start of the year, followed by Stryker’s divestiture of its U.S. spine business4Stryker completes sale of U.S. spinal implants business. (2025, January 4). Stryker. https://investors.stryker.com/press-releases/news-details/2025/Stryker-completes-sale-of-U-S–spinal-implants-business/default.aspx, and Johnson & Johnson’s announced intent to separate its $9 billion orthopedics unit, DePuy Synthes5Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business. (2025, October 14). Johnson & Johnson Investor News. https://www.investor.jnj.com/investor-news/news-details/2025/Johnson–Johnson-Announces-Intent-to-Separate-Its-Orthopaedics-Business/default.aspx.
In this article, Alcimed examines the evolving dynamics of the MedTech M&A landscape, highlighting the strategic priorities expected to shape dealmaking in 2026.
The momentum from 2025 is carrying decisively into 2026. After a year defined by selective, high-value consolidation, the MedTech M&A will likely be shaped less by deal volume and more by strategic focus areas, including digital transformation, AI-enabled workflows, and portfolio realignment to capture emerging clinical and market opportunities. Acquirers are increasingly deploying M&A as a strategic instrument to future-proof their businesses against structural shifts in care delivery, technology adoption, and patient demographics.
In 2026, artificial intelligence will no longer be viewed as an optional growth lever or a speculative bet. Instead, AI maturity is becoming a gating item for valuation. Acquirers are assigning premium multiples only to targets that can demonstrate validated, regulator-ready AI solutions with clear clinical and operational impact.
The market has moved decisively beyond concept-stage algorithms and pilot studies. Buyers are prioritizing AI technologies that integrate seamlessly into clinical workflows, reduce administrative burden for clinicians, or demonstrably improve diagnostic accuracy and decision-making.
Rather than building these capabilities in-house, both strategic acquirers and private equity sponsors are increasingly turning to M&A – not just strategic alliances – to secure AI and GenAI assets. Market outlooks consistently highlight AI-enabled workflow platforms and healthcare data infrastructure as core M&A hotspots for 2026. The underlying message is clear: in MedTech, value is now assigned to AI performance, not just potential. For a detailed overview of the current AI landscape in healthcare, Alcimed’s AI & Healthcare Atlas provides a comprehensive map of key technologies, applications, and market opportunities.
Another key theme for 2026 is the ongoing shift of care from traditional hospital settings toward lower-cost, higher-throughput ambulatory and outpatient environments. M&A activity is increasingly focused on technologies that enable high-volume procedures (e.g., in orthopedics and cardiology) to be safely and efficiently performed outside the hospital, including in Ambulatory Surgery Centers (ASCs) and other outpatient care models.
This trend is driven by reimbursement pressures, capacity constraints in acute care hospitals, and patient preference for faster, less resource-intensive care pathways. Companies are responding by acquiring technologies that support these new care models, including minimally invasive devices, enabling capital equipment, digital perioperative tools, and integrated care platforms purpose-built for outpatient and ambulatory settings.
Read also: 3 key challenges for reimbursement of innovative medical devices
In addition, digital and remote monitoring solutions are playing an increasingly important role, enabling at-home diagnostics, continuous patient monitoring, and tools that support quality of life for chronic and oncology patients. Integrating these technologies into care pathways not only improves outcomes but also strengthens the value proposition of assets in M&A transactions.
For MedTech companies, exposure to the ambulatory and outpatient ecosystem is no longer a peripheral growth option, but a strategic necessity. Assets that demonstrate scalability, cost efficiency, and strong adoption in these care settings are expected to attract heightened strategic interest and valuation premiums throughout 2026.
The current rapid and widespread adoption of GLP-1 weight-loss drugs represents one of the most significant structural disruptions facing the MedTech industry. These therapies have the potential to reduce device utilization across multiple obesity-linked segments, including sleep apnea, diabetes management, orthopedics, and cardiovascular care.
In response, MedTech companies are increasingly using M&A as both a defensive and offensive tool to GLP-1 proof their portfolios. This strategy is not about resisting the shift toward pharmacological intervention, but about adapting to the new clinical landscape it creates.
On the defensive side, acquirers are seeking assets that are relatively insulated from declining procedure volumes. More strategically, companies are expanding into technologies that address advanced and downstream complications of obesity and diabetes, including venous thromboembolism, advanced heart failure, and complex cardiovascular disease, where device-based intervention remains unavoidable even as GLP-1 adoption accelerates. Again, Stryker’s 2025 acquisition of Inari Medical exemplifies this approach, anchoring portfolio growth in late-stage thromboembolic disease that persists downstream of long-standing metabolic dysfunction and remains largely unaffected by weight-loss drugs.
Offensively, MedTech players are beginning to pursue acquisitions that position them within broader metabolic management platforms, enabling longitudinal disease monitoring and care coordination across evolving treatment pathways. While still emerging, these moves reflect an effort to remain central to metabolic care regardless of how frontline obesity treatment evolves. GE HealthCare’s 2025 acquisition of Intelerad illustrates this shift, expanding GEHC’s footprint in enterprise imaging and workflow infrastructure that underpins the diagnosis and long-term management of cardiometabolic disease. Rather than competing with GLP-1 therapies, such platforms allow MedTech companies to embed themselves across the full metabolic care continuum.
The MedTech M&A landscape in 2026 is shaping up for a selective but high-value resurgence. Companies that align their portfolios around high-growth therapeutic segments, validated AI-native capabilities, and technologies enabling care migration to ambulatory settings will be best positioned to capture strategic value.
At the same time, dealmakers will need to remain mindful of broader market and regulatory dynamics. Geopolitical pressures, such as trade tariffs and supply chain localization, may influence asset valuations. Intensifying antitrust scrutiny could lengthen deal timelines or even block them, as shown in January 2026 with the FTC blocking Edwards Lifesciences’ $945M acquisition of heart implant developer JenaValve1FTC wins case blocking Edwards’ $945M JenaValve takeover. (2026, January 12). Fierce Biotech. https://www.fiercebiotech.com/medtech/ftc-wins-case-blocking-edwards-945m-jenavalve-takeover. Meanwhile, the gradual reopening of public markets provides alternative pathways for emerging innovators.
The key questions for 2026 will therefore be: How will companies balance strategic ambition with regulatory and geopolitical uncertainty? Which assets are truly “future-proof” in an era of rapid technological and clinical shifts? How can M&A be used to proactively adapt to evolving patient needs, rather than simply react to disruption?
Ultimately, 2026 will reward disciplined, forward-looking M&A, not in isolation, but through the ability to simultaneously address these three defining questions. Companies that can balance ambition with uncertainty, identify genuinely future-proof assets, and deploy M&A proactively around patient needs will define the next wave of MedTech leadership.
About the author,
Leendert, Consultant in Alcimed’s Life Sciences team in the USA
Healthcare
What technologies are used for medical remote monitoring? Medical remote monitoring requires appropriate equipment, including sensors, mobile applications and digital platforms, AI, integrated ...
Healthcare
The SNITEM symposium revealed 3 challenges for enhancing the sustainability of the medical device industry. What are these challenges?
Articles
Can technology help treat mental illness? These 5 mental health technologies are proof that tech can greatly improve care and efficacy of current therapies.